MiMedx Group is trading at $4.00 (6.3% down) in after-hours trading following its July 29 earnings release and the announcement of a $350 million deal to acquire Sanara MedTech.
- The company reported a sharp year-over-year revenue decline driven by Medicare reimbursement changes in its Wound segment, which was partially offset by growth in the Surgical segment.
- Investors are currently digesting the strategic implications of the $350 million Sanara MedTech acquisition alongside the mixed quarterly performance.